Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results
Moleculin Biotech's Annamycin shows 43% leukemia remission as MIRACLE data heads to ASH 2026. See what the early 2027 readout could reveal.
Pharma & Biotech
Pharma & Biotech
Moleculin reports 37% blinded remission rate as Annamycin AML trial nears critical readout
Moleculin Biotech has reported a preliminary 37% composite complete remission rate among 62 evaluable patients in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia. The July 31 update also showed a 24% complete remission rate across the blinded study population. Among 30 evaluable
Pharma & Biotech
New MIRACLE data examine remission after venetoclax failure in relapsed AML
MIRACLE reports a 37% blinded composite remission rate in relapsed AML, including patients who previously failed venetoclax treatment.
Pharma & Biotech
Can Annamycin bridge cytotoxic therapy and immunotherapy in pancreatic cancer?
Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.
Pharma & Biotech
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
Pharma & Biotech
How annamycin’s clean cardiac safety profile may strengthen Moleculin’s oncology development strategy
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.